Arcutis Biotherapeutics (NASDAQ:ARQT – Get Free Report) and Jaguar Animal Health (NASDAQ:JAGX – Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, risk and profitability.
Profitability
This table compares Arcutis Biotherapeutics and Jaguar Animal Health’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Arcutis Biotherapeutics | 6.15% | 15.05% | 6.51% |
| Jaguar Animal Health | -187.88% | N/A | -131.45% |
Earnings and Valuation
This table compares Arcutis Biotherapeutics and Jaguar Animal Health”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Arcutis Biotherapeutics | $376.07 million | 7.99 | -$16.14 million | $0.21 | 113.90 |
| Jaguar Animal Health | $11.51 million | 0.17 | -$53.43 million | ($3,731.33) | -0.00 |
Arcutis Biotherapeutics has higher revenue and earnings than Jaguar Animal Health. Jaguar Animal Health is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
12.0% of Jaguar Animal Health shares are owned by institutional investors. 9.4% of Arcutis Biotherapeutics shares are owned by insiders. Comparatively, 0.2% of Jaguar Animal Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Analyst Ratings
This is a breakdown of recent ratings and target prices for Arcutis Biotherapeutics and Jaguar Animal Health, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Arcutis Biotherapeutics | 0 | 3 | 6 | 0 | 2.67 |
| Jaguar Animal Health | 1 | 0 | 0 | 0 | 1.00 |
Arcutis Biotherapeutics presently has a consensus target price of $35.57, suggesting a potential upside of 48.71%. Given Arcutis Biotherapeutics’ stronger consensus rating and higher probable upside, research analysts plainly believe Arcutis Biotherapeutics is more favorable than Jaguar Animal Health.
Risk and Volatility
Arcutis Biotherapeutics has a beta of 1.57, suggesting that its stock price is 57% more volatile than the S&P 500. Comparatively, Jaguar Animal Health has a beta of -0.11, suggesting that its stock price is 111% less volatile than the S&P 500.
Summary
Arcutis Biotherapeutics beats Jaguar Animal Health on 13 of the 14 factors compared between the two stocks.
About Arcutis Biotherapeutics
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
About Jaguar Animal Health
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.
Receive News & Ratings for Arcutis Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcutis Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
